ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements with these filters
Mangalam Drugs and Organics Limited announced the appointment of new Statutory and Secretarial Auditors following the tenure completion of the previous Statutory Auditor.
Manglam Drugs and Organics Ltd. has appointed M/s S.N. Nanda & Co. as Statutory Auditor and M/s L.N. Joshi & Co. as Secretarial Auditor.
Mangalam Drugs and Organics Ltd held its 53rd Annual General Meeting on September 23, 2026. The meeting transacted standard business items including financial statement adoption and auditor appointments.
Mangalam Drugs and Organics reported a bank default amounting to Rs. 15.57 Crore. The company has submitted a restructuring proposal to the banks for resolution.
Mangalam Drugs disclosed a default on loan obligations to Bank of Maharashtra and Bank of Baroda, totaling ₹15.57 Crore in overdue amounts.
Mangalam Drugs and Organics Limited has appointed Mr. Prabhakar Raghunath Zavar as a Non-Executive Independent Director, effective September 15, 2026.
Mangalam Drugs & Organics appointed Mr. Prabhakar Raghunath Zavar as an Additional Independent Non-Executive Director for a five-year term at the latest board meeting.
Mangalam Drugs and Organics Limited scheduled its 53rd Annual General Meeting for September 23, 2026. The meeting will be held via video conferencing.
Mangalam Drugs disclosed defaults on loan obligations to Bank of Baroda and Bank of Maharashtra, totaling ₹15.57 Crore in overdue amounts.
Mangalam Drugs and Organics Ltd reported revenue from operations of ₹57.1 Cr (-0.2% YoY) and a net loss of ₹7.6 Cr for Q1 FY27.
Mangalam Drugs and Organics Limited announced the cessation of its Secretarial Auditor, M/s. Ragini Chokshi & Co., due to resignation effective August 4, 2026.
Mangalam Drugs and Organics Limited informed the exchanges that M/s. Ragini Chokshi & Co. has resigned as the company's Secretarial Auditor effective August 4, 2026.
Mangalam Drugs & Organics will hold a board meeting on August 12, 2026, to consider unaudited financial results and appoint auditors.
Mangalam Drugs and Organics reported a Rs. 15.57 Crore default on cash credit facilities. The defaults involve Bank of Baroda and Bank of Maharashtra accounts.
Mangalam Drugs reported a Rs.15.57 Crore bank default. The company has submitted a restructuring proposal to lenders to address the liability.
Mangalam Drugs and Organics reported a Rs 15.57 Crore default on cash credit facilities from two banks. The company is arranging funds to clear the overdue amounts.